Clinical Trial

Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment in subjects with Immunoglobulin G4 Related Disease (IgG4-RD)
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-07-09; most recent amendment 2026-02-12.
Status change: Not Yet Recruiting → Recruiting 2026-01-22
Trial Details
NCT Number NCT07061938
Lead Sponsor Acepodia Biotech, Inc.
Conditions IgG4 Related Disease
Enrollment 30 participants
Start Date 2026-01-01
Primary Completion 2027-01-20 (estimated)
Study Completion 2027-06-20 (estimated)
Updated on ClinicalTrials.gov 2026-02-13